Four groups of 12 subjects received 10 ( 9 ) to 10 ( 11 ) viral particles ( vp ) of the Ad5HVR48.EnvA .01 vaccine ( n = 10 per group ) or placebo ( n = 2 per group ) at week 0 or weeks 0 , 4 , and 24 .